Bo Ahrén
21 – 30 of 393
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5).
(
- Contribution to journal › Article
-
Mark
Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice
2019) In American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 316(1). p.27-37(
- Contribution to journal › Article
-
Mark
Glucagon-like peptide-1 receptor agonists for type 2 diabetes : A rational drug development
(
- Contribution to journal › Article
-
Mark
Islet adaptation in GIP receptor knockout mice
2019) In Peptides(
- Contribution to journal › Scientific review
-
Mark
Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections
(
- Contribution to journal › Article
-
Mark
Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
(
- Contribution to journal › Article
-
Mark
DPP-4 inhibition and the path to clinical proof
(
- Contribution to journal › Article
-
Mark
Reductioninglycatedhemoglobin and daily insulin dose alongside circadian clock upregulation in patients with type 2 diabetes consuming a three-meal diet : A randomized clinical trial
(
- Contribution to journal › Article
- 2018
-
Mark
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
(
- Contribution to journal › Article
-
Mark
Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients
(
- Contribution to journal › Article